Health and Healthcare
Biopharma Companies to Watch This Week and for the Rest of June
Published:
Last Updated:
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Global Blood Therapeutics Inc. (NASDAQ: GBT) is making a presentation at the SCD Research and Educational Symposium on June 15 to 17. Shares of GBT were last seen at $48.05 on Friday, with a consensus analyst price target of $72.46 and a 52-week trading range of $24.02 to $68.05.
Argenx S.E. (NASDAQ: ARGX) is making a presentation at the Immune Thrombocytopenia Breakfast Symposium on June 19 for its human monoclonal antibody Efgartigimod (ARGX 113). Argenx shares were trading at $99.95 on Friday, with a consensus price target of $91.01 and a 52-week range of $19.00 to $101.46.
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is making presentations at the American Diabetes Association on June 22 to 26. Lexicon recently traded at $12.92 a share, with a consensus price target of $23.00 and a 52-week range of $7.67 to $18.00.
Achaogen Inc. (NASDAQ: AKAO) has a Prescription Drug User Fee Act (PDUFA) date scheduled for June 25 for its lead product plazomicin, which is being developed to treat serious bacterial infections. Achaogen shares traded at $11.98, with a consensus price target of $18.20 and a 52-week range of $9.83 to $25.22.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is readying for its commercial launch of Palynziq (pegvaliase) in the United States, for the treatment of phenylketonuria. Shares of BioMarin were trading at $90.56, with a consensus analyst target of $111.14 and a 52-week range of $75.81 to $100.03.
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
